logo
Share SHARE
FONT-SIZE Plus   Neg

Forest Labs, Pierre Fabre Report Results In Phase III Trial Of Levomilnacipran

Forest Laboratories, Inc. (FRX: Quote) and Pierre Fabre Medicament announced positive top-line results in a Phase III clinical trial of levomilnacipran, an investigational agent for the treatment of adults with major depressive disorder, or MDD.

Treatment with levomilnacipran significantly reduced depression symptoms in patients with MDD versus placebo, as early as week one and at each subsequent visit as measured by the Montgomery-Asberg Depression Rating Scale-Clinician Rated. Levomilnacipran was generally well-tolerated in this study. The premature discontinuation rates were 25 percent for levomilnacipran and 21 percent for placebo. The most common adverse events observed in the levomilnacipran group were nausea, dizziness and constipation.

Results from an additional placebo-controlled Phase III fixed-dose study are expected in Spring 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Apple will unveil its Apple Watch with a battery that may last only 2.5 to 4 hours on very active use, according to a report in 9to5mac. "People with knowledge of the Apple Watch's development have provided us with the specific performance targets Apple wants to achieve for the Apple Watch battery,... HARMAN International Industries, Inc. (HAR) announced it has signed an agreement with Symphony Technology Group to acquire Symphony Teleca, a privately-held global software services company. Check out this story for a look at some of We are just a few weeks into 2015 and it has already been a busy year for merger deals and merger talks. Here is a list of some of the M&A stories that have made headlines so far in 2015.
comments powered by Disqus
Follow RTT